Skip to main content

Table 1 Characteristics of included trials

From: Neuromuscular blocking agents in acute respiratory distress syndrome: a systematic review and meta-analysis of randomized controlled trials

Study Number (sites) Target patients Experimental intervention Control intervention Lung protection
Gainnier 2004 [12] 56 ARDS 48-hour infusion cisatracurium 48-hour infusion placebo (bedside nurse not blinded) ARMA protocol; no weaning protocol
  (4) PaO2/FiO2 < 150 (weight-based, and adapted to peripheral nerve stimulation)   
   Eligible < 36 hours    
   Exclude prior NMBA    
Forel 2006 [13] 36 ARDS 48-hour infusion cisatracurium 48-hour infusion placebo (bedside nurse not blinded) ARMA protocol; no weaning protocol
  (3) Intubated < 48 hours (weight-based and adapted to peripheral nerve stimulation)   
   PaO2/FiO2 < 200    
   Exclude recent steroids or NMBA    
Papazian 2010 [14] 340 ARDS 48-hour infusion cisatracurium 48-hour infusion placebo ARMA protocol; weaning protocol
  (20) PaO2/FiO2 < 150 (high-dose, with no peripheral nerve stimulation)   
   Eligible < 48 hours    
   Exclude prior NMBA    
  1. ARDS, Acute respiratory distress syndrome; NMBA, neuromuscular blocking agent; ARMA, the Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome [4].